bevacizumabmCRCtrifluridine/tipiracilmetastatic colorectal cancerBev-TASsecond-level hospital
…in the pivotal SUNLIGHT trial, supporting the benefit of adding bevacizumab to trifluridine/tipiracil in real-world practice. Safety profil…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 448 of 2459AntithromboticsADEsinterventionmedication
… events (ADEs) can result in severe patient harm or even death. Antithrombotics are frequently implicated in (fatal) ADEs. In Dutch pharmacies,…
inflammatory bowel diseaseazathioprinemesalazineLin et al
…suppressor of narrow therapeutic range (0.157-0.3mg/L), used in inflammatory bowel disease. Its metabolism includes enzymes as TPMT and NUDT15, which poly…
omalizumabsevere asthmaasthma
…ime since severe asthma diagnosis was 6 (±6) years, with a mean omalizumab treatment persistence of 5 (±4) years and a Dm of 477 (±115) mg…
oncologyMicromedexOncoAssistUpToDateDrugBankAIs
…nce Drug–drug interactions (DDIs) are a major safety concern in oncology. These interactions may arise from pharmacokinetic or pharmacod…
evinacumabsevere hypercholesterolaemiahomozygous familial hypercholesterolaemia (HoFH)monotherapyezetimibetertiary-level hospital
…h homozygous familial hypercholesterolaemia (HoFH) treated with evinacumab 15 mg/kg IV every 4 weeks between February 2024 and September 2…
nivolumabpembrolizumabcarboplatinipilimumaboxaliplatinpaclitaxelchemotherapyCzech State Institute for Drug ControlCharles University grant SVV 260 785immunotherapy-related+2 more
…gical therapy (21%), and other (9%). Most implicated drugs were nivolumab, ipilimumab, carboplatin, paclitaxel, oxaliplatin, and pembroli…
voriconazoletertiary level hospitalinflammationinflammatory processes
…here may be situations of intoxication by certain drugs such as voriconazole.Aim and Objectives To analyse the influence between C-reactive …
TocilizumabCRSuniversity hospitalmultiorgan failureCAR-T cell therapies
….2%; grade 2: 77.8%]; CAR-T: 90% [grade 1: 65%; grade 2: 25%]). Tocilizumab was used less frequently for BsAb-related CRS (77.8% vs 100%). …
breast cancerpaclitaxelEpirubicinepirubicin-cyclophosphamidePtertiary hospital
…ortance Dose-dense (DD) chemotherapy has been incorporated into breast cancer management with the objective of enhancing therapeutic efficacy…
migraineAtogepanttertiary hospital
…ents had chronic migraine, while 5 (7.9%) patients had episodic migraine. Regarding previous treatments, 56 (88.9%) patients had receive…
pembrolizumabtertiary hospitalNSCLCImmune checkpoint inhibitorsmetastatic non-small-cell lung adenocarcinomaproton pump inhibitors
… may negatively impact both PFS and OS in patients treated with pembrolizumab. These findings, consistent with previous literature, highlight…